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OBJECTIVES The purpose of this study was to determine whether administration of estrogen produces
cardioprotective effects in patients undergoing coronary angioplasty.
BACKGROUND We have previously demonstrated that estrogen can provide cardioprotection by activating the
mitochondrial adenosine triphosphate-sensitive potassium (KATP) channel, a major contrib-
utor to ischemic cardioprotection.
METHODS Fifty patients undergoing angioplasty of a major epicardial coronary artery were randomly
allocated to either ischemic preconditioning or intracoronary estrogen administration in the
presence or absence of glibenclamide (glyburide).
RESULTS The coronary collateral circulation, as quantitatively assessed by an intracoronary Doppler
flow wire, was similar during balloon inflation among the groups. Patients in the precondi-
tioned and estrogen-treated groups significantly lowered their ischemic burden, as assessed by
an ST-segment shift, chest pain score and myocardial lactate extraction ratio, as compared
with control subjects. The reduction in the ST-segment shift afforded by estrogen during the
first inflation (63% vs. first inflation in the preconditioned group) was similar to that
afforded by preconditioning during the second inflation (68% vs. first inflation). In contrast,
the patients given glibenclamide developed significantly higher ischemic burden during the
first and second inflations, as compared with those in the estrogen-treated group alone.
CONCLUSIONS It is concluded that intracoronary administration of estrogen before balloon angioplasty
rendered the myocardium relatively resistant to subsequent ischemia, and the degree of
cardioprotective effect was comparable to that afforded by ischemic preconditioning. The
effect of estrogen was abolished by glibenclamide, suggesting that the cardioprotective effect
of estrogen may result from activation of myocardial KATP channels. (J Am Coll Cardiol
2002;39:871–7) © 2002 by the American College of Cardiology Foundation
Coronary artery disease is the leading cause of death in
women, especially among postmenopausal women (1). Es-
trogen levels drop markedly after menopause. Epidemiologic
studies have shown that estrogen replacement can significantly
reduce cardiovascular morbidity by 50% in menopausal women
(2), although the mechanism remains unclear. Estrogen has
previously been shown to exert cardioprotective effects in the
dog (3–5). The cardioprotective effects of estrogen have been
attributed to antioxidants (3), increased nitric oxide release (4)
and the opening of calcium-activated potassium channels (5).
Our previous study showed that 17-beta-estradiol administra-
tion provided cardioprotection produced by activation of aden-
osine triphosphate-sensitive potassium (KATP) channels in
canine hearts (6). However, no previous study has addressed
the issue of the effects of estrogen in humans on KATP channels
during myocardial ischemia.
Ischemic preconditioning is a cardioprotective phenom-
enon in which short periods of myocardial ischemia result in
the myocardium’s resistance to a subsequent stress (7). The
model of percutaneous transluminal coronary angioplasty
(PTCA) as a surrogate of ischemia-reperfusion has gained
popularity for assessing the ability of various agents to
mimic preconditioning (8). Ischemic preconditioning is
thought to be mediated by mitochondrial KATP channels
(6). The opening of these channels may be important in
ischemic preconditioning, because inhibition of KATP chan-
nels with glibenclamide (glyburide) abolishes the cardiopro-
tective effects of ischemic preconditioning in both experi-
mental and clinical studies (9,10). The use of agents to open
this channel may mimic a physiologic response that acts to
attenuate ischemic injury. Thus, this study investigates
whether pretreatment of intracoronary estrogen potentiates
ischemic preconditioning before balloon inflations in pa-
tients undergoing PTCA. We have also investigated
whether the observed cardioprotective effects of estrogen are
caused by the activation of KATP channels through the use
of glibenclamide, a KATP channel blocker.
METHODS
Study group. The study was conducted prospectively. All
patients fulfilled the entry criteria: 1) a history of chronic,
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stable angina pectoris 3 months and a positive standard
stress test for myocardial ischemia; 2) no history on the
electrocardiogram (ECG) of a previous myocardial infarc-
tion, nor pathologic Q waves or bundle branch block, which
could have interfered with the interpretation of ST-segment
changes; 3) no angiographically visible collateral blood flow
at baseline, so that the collateral circulation of the study
patients was homogeneous; 4) a single proximal or mid-
epicardial coronary artery lesion with 70% to 90% reduction
in the lumen diameter; and 5) successful balloon angioplasty
resulting in residual stenosis 30%. No patient had a
history of diabetes mellitus. Women included in this study
were confirmed to have been menopausal for at least five
years by measuring their serum follicle-stimulating hormone
and estrogen levels. No patient had received hormone
replacement therapy for at least six months before the study
began. Medications, including calcium channel blockers and
beta-blockers, were held for 24 h before the procedure. Any
patient who had taken nitroglycerin within 4 h of catheter-
ization was excluded from the study. A consecutive total of
50 patients were included. Patients were randomly allocated
to one of the five groups (Fig. 1). The study was approved
by the National Taiwan University Hospital Review Board,
and all subjects provided written, informed consent before
participation.
Study protocol. CATHETERIZATION PROCEDURES. Diag-
nostic left heart catheterization and angiography were per-
formed from a femoral approach, as previously described
(11). After completion of diagnostic catheterization, intra-
venous heparin was supplemented to maintain an activated
clotting time of 300 to 350 s, and a 6F Judkin’s guiding
catheter was advanced to the ostium of the left or right
coronary artery. To assess collateral flow during coronary
occlusion, a 0.014-in. (0.035-cm) Doppler wire (FloWire,
Cardiometrics, Inc., Mountain View, California) was first
introduced through a standard angioplasty-type Y-connector
attached to the angiographic catheter. The wire tip was
positioned such that a characteristic and stable flow velocity
waveform was obtained. Collateral flow during balloon
inflations was determined by the sum of systolic and
diastolic collateral blood flow velocity integrals, as previ-
ously described (12). The distal segment of the guide wire
was placed 2 to 3 cm beyond the balloon catheter tip. The
external end of the guide wire was connected to the chest
lead by a sterile alligator clamp to record the intracoronary
ECG. Multiple pairs of perpendicular views (90°) of the left
and right coronary arteries were obtained. The precise angle,
skew rotation and table height of each projection were
recorded to allow the projection to be duplicated. Quanti-
tative measurements of coronary artery dimensions were
Abbreviations and Acronyms
ANOVA  analysis of variance
ECG  electrocardiogram
HERS  Heart and Estrogen/progestin Replacement
Study
KATP  adenosine triphosphate-sensitive potassium
MLER  myocardial lactate extraction ratio
PTCA  percutaneous transluminal coronary
angioplasty
Figure 1. Summary of study protocol. Black boxes  period of balloon inflation; arrows  intracoronary electrocardiograms and chest anginal score;
arrowheads  lactate measurements from the great cardiac vein and the aorta simultaneously. Est  estrogen; Glib  glibenclamide; PC 
preconditioning; S  seconds.
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made using a computer-based edge enhancement technique
(DCI System, Philips, Inc., Best, The Netherlands), as
previously described (11). Nonionic contrast medium was
used in all patients to prevent a myocardial depressant effect
during coronary angiography. Blood pressure and heart rate
were continuously monitored during the procedure. Patients
were not sedated.
ANGIOPLASTY PROCEDURE. After angiographic collateral
assessment and intracoronary ECG monitoring, intracoro-
nary estrogen (Premarin, 5 mg, Wyeth-Ayerst, Radnor,
Pennsylvania) was administered through the guiding cath-
eter. The control group was injected with a bolus of the
same volume of normal saline. After a 10-min drug-free
period, the lesion was crossed with a balloon. To determine
the potential role of KATP channels in estrogen-induced
preconditioning, glibenclamide (10 mg) was orally admin-
istered 60 min before catheterization with a continuous
infusion of 10% dextrose at the same time. The optimal
balloon size was determined by quantitative evaluation of
the coronary artery diameters adjacent to the stenosis. After
the balloon was positioned across the lesion, the patients
underwent two 2-min balloon inflations separated by 1- or
2-min intervals of reperfusion (Fig. 1), with the Doppler
guide wire remaining across the lesion at the same site for
each successive recording. A recovery time of 1 min was
adequate to re-establish baseline nonischemic conditions, as
assessed by intracoronary electrocardiography and chest
pain. An interval of 2 min between balloon inflations was
used to produce preconditioning (13). During the reperfu-
sion intervals, the angioplasty balloons were withdrawn
from the stenotic site, and the guide wire was left at the
same position. Because balloon pressure is a determinant of
cardiac pain during PTCA (14), identical balloon pressure
was maintained during the first and second inflations in each
patient, with inflation pressures ranging from 6 to 10 atm.
ASSESSMENT OF MYOCARDIAL ISCHEMIA. The intracoro-
nary ECG was recorded on-line at a paper speed of 25 mm/s
during the two balloon inflations and at selected times after
deflation. Calibration was performed at the beginning of
the procedure (1 mV  5 mm). At all time points, the
ST-segment shift was measured 80 ms after the J point on
a minimum of three complexes. ST-segment elevation was
evaluated in a blinded manner by two observers (T. M. L.,
C. H. T.) who viewed the ECGs in random order, without
knowledge of which patient was being presented. Differ-
ences in interpretation were resolved by consensus. Changes
in ST-segment levels at baseline were used as the control,
and differences in ST-segment levels recorded between the
control value and at the end of the first and second inflations
were compared to evaluate the severity of myocardial isch-
emia.
To confirm myocardial ischemia during balloon infla-
tions, selective catheterization of the great cardiac vein was
successfully attempted. Simultaneous samples of aortic root
and coronary sinus blood withdrawn at identical sampling
rates were obtained for measurements of lactate contents.
The myocardial lactate extraction ratio (MLER) was calcu-
lated by the following formula:
LAR  LCS/LAR  100
where LAR and LCS represent plasma lactate concentrations
in the aortic root and coronary sinus, respectively.
ASSESSMENT OF CHEST PAIN. Before PTCA, patients were
informed that they might develop chest pain during balloon
inflation. Immediately before termination of balloon infla-
tion, patients were asked to quantify the intensity of chest
pain by using a visual-analog scale (15) on a scale of 0 (no
pain) to 10 (most severe pain).
LABORATORY MEASUREMENTS. Coronary sinus blood, re-
flecting the local concentrations, was sampled for measure-
ment of plasma estrogen levels at baseline and at the end of
the study, 60 min after administration. Estrogen concen-
trations were quantified by enzyme-linked immunosorbent
assay (Diagnostic Products Corp., Los Angeles, California).
The detection limit was 10 pg/ml for 17-beta-estradiol. To
determine the confounding roles of glucose in ischemic
preconditioning, sinus blood samples for glucose concentra-
tions were assayed.
Statistics. Continuous variables are expressed as the mean
value 	 SD. The groups of patients were analyzed using
analysis of variance (ANOVA). Two-way repeated-
measures ANOVA was used to search for the possible
effects of estrogen and glibenclamide on the measurements
of intracoronary electrocardiography and lactate levels and,
if an F value was found to be significant, the two-tailed
Student t test for paired observations, with the Bonferroni
correction, was used to test differences. The interaction term
of estrogen and glibenclamide effects was incorporated into
the model. Visual analog scales were analyzed using the
Wilcoxon signed rank test. Chi-square analysis was used for
categoric variables, and the Fisher exact test was used for
patient numbers 5. Probability values are two-tailed, and
a p value 0.05 is considered to be statistically significant.
RESULTS
The clinical features of the patients are outlined in Table 1.
There were no significant differences among the groups in
terms of the patients’ age, gender and frequency of cardio-
vascular risk factors. Coronary stenosis was similarly re-
duced among the groups (Table 2). Glucose levels remained
stable throughout the study. The balloon pressure used was
similar. No myocardial injury was reflected in any patients
after PTCA, as assessed by electrocardiography.
Coronary sinus plasma estrogen concentrations. There
were no significant differences in estrogen concentrations
among the groups at baseline (Table 1). After estrogen
administration, there was a significant increase at the end of
the study.
Hemodynamic data. No significant changes were seen in
the mean blood pressure and heart rate among the five
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groups at baseline and after the first and second angioplas-
ties. The rate-pressure product, an index of oxygen con-
sumption, was comparable among the five groups.
Collateral circulation. The quantitative variables used to
assess the collateral circulation and obtained during the first
and second balloon inflations indicated the presence of
low-grade collateral channels and did not differ between the
study groups (Table 3).
Myocardial ischemia. CHEST PAIN. Before each inflation,
all patients were asymptomatic. In the control group, the
severity of chest pain was similar between the first and
second inflations. Chest pain in the preconditioned group
during the second inflation was significantly less than during
the first inflation, indicating effective ischemic precondi-
tioning. In contrast, the chest pain score during the first
inflation was significantly less in the estrogen-treated group
than in the other groups. In patients treated with estrogen,
the pain was the same during the first and second inflations.
Although patients in the preconditioned and estrogen-
treated groups experienced less anginal severity during the
second inflation, chest pain was significantly increased in
patients pretreated with glibenclamide.
INTRACORONARY ELECTROCARDIOGRAPHY. The ST-
segment shift values at the end of the two inflations are
reported in Table 3. Before each inflation, there was no
ST-segment shift on the intracoronary ECG. In the control
group, the mean ST-segment shift during the second
Table 1. Clinical Characteristics and Estrogen Concentrations
Variables
Control
(n  10)
PC
(n  10)
Estrogen
(n  10)
PC 
Glibenclamide
(n  10)
Estrogen 
Glibenclamide
(n  10)
Age (yrs) 53 	 6 51 	 4 53 	 8 55 	 6 53 	 7
Male/female 9/1 8/2 9/1 10/0 9/1
CAD risk factor
Hypertension (%) 5 (50) 4 (40) 4 (40) 5 (50) 5 (50)
Smoking (%) 3 (30) 4 (40) 4 (40) 4 (40) 3 (30)
Total cholesterol (mg/dl) 221 	 34 201 	 43 220 	 38 221 	 26 230 	 18
Triglycerides (mg/dl) 233 	 76 257 	 55 252 	 57 249 	 62 245 	 49
Vessel disease
LAD 8 9 8 8 8
LCx 1 1 2 1 0
RCA 1 0 0 1 2
17-beta-estradiol (pg/ml)
Baseline 26 	 3 26 	 2 25 	 2 24 	 3 26 	 2
At end of study 24 	 3 22 	 4 94 	 8* 23 	 4 118 	 6*
*p  0.0001 compared with respective baseline data and the groups without estrogen administration at the end of the study. Data
are presented as the mean value 	 SD or number (%) of patients or control subjects.
CAD  coronary artery disease; LAD  left anterior descending coronary artery; LCx  left circumflex coronary artery;
PC  preconditioning; RCA  right coronary artery.
Table 2. Hemodynamic Data
Variables
Control
(n  10)
PC
(n  10)
Estrogen
(n  10)
PC 
Glibenclamide
(n  10)
Estrogen 
Glibenclamide
(n  10)
Mean blood pressure (mm Hg)
Baseline 92 	 9 98 	 12 96 	 15 97 	 15 98 	 16
Inflation 1 95 	 11 94 	 15 92 	 12 97 	 14 94 	 15
Inflation 2 95 	 12 94 	 10 99 	 10 95 	 13 93 	 13
Heart rate (beats/min)
Baseline 65 	 6 67 	 9 67 	 7 67 	 7 66 	 6
Inflation 1 66 	 7 71 	 11 68 	 8 68 	 10 65 	 7
Inflation 2 70 	 10 68 	 8 68 	 6 68 	 8 68 	 11
RPP (
103)
Baseline 8.92 	 1.98 9.24 	 1.33 9.22 	 1.71 9.18 	 2.17 9.17 	 1.46
Inflation 1 9.13 	 1.88 9.31 	 1.43 9.26 	 1.12 9.24 	 1.23 9.15 	 1.16
Inflation 2 8.97 	 1.85 9.22 	 1.17 9.47 	 1.32 9.25 	 1.26 9.37 	 1.14
Severity of stenosis (%)
Before angioplasty 80 	 4 80 	 5 79 	 4 79 	 5 79 	 4
After angioplasty 19 	 6 19 	 4 18 	 6 20 	 4 17 	 5
Inflation pressure (atm)
Inflation 1 7.3 	 1.3 7.0 	 0.9 7.0 	 1.1 7.1 	 1.0 7.1 	 1.0
Inflation 2 7.3 	 1.3 7.0 	 0.9 7.0 	 1.1 7.1 	 1.0 7.1 	 1.0
Data are presented as the mean value 	 SD.
RPP  rate–pressure product; other abbreviations as in Table 1.
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balloon inflation was similar to that observed during the first
inflation (1.46 	 0.26 mV vs. 1.48 	 0.21 mV, p  NS). In
the preconditioned patients, the ST-segment shift was
significantly greater during the first inflation than during the
second inflation, consistent with ischemic preconditioning.
In the estrogen-treated patients, the changes in ST-segment
shift were similar between the first and second inflations
(0.50 	 0.16 mV vs. 0.47 	 0.09 mV, p  NS). The
reduction in the ST-segment shift afforded by estrogen
during the first inflation (63% vs. first inflation in the
preconditioned group) was similar to that afforded by
preconditioning during the second inflation (68% vs. first
inflation). In contrast, the patients who received gliben-
clamide developed a higher ST-segment shift during the
first and second inflations, as compared with those in the
estrogen-treated group alone.
LACTATE MEASUREMENTS. The respective baseline values
were positive and similar, indicating the absence of signif-
icant lactate production in the pre-angioplasty state. The
MLER was more negative in the control group than in the
preconditioned and estrogen groups during the second
inflation, indicating less lactate production from the isch-
emic myocardium in the latter two groups. The benefits of
metabolic features were abolished after glibenclamide ad-
ministration.
DISCUSSION
This study showed that pretreatment with estrogen pro-
vided myocardial adaptation to ischemia during coronary
PTCA that was as effective as preconditioning and was
independent of collateral channel recruitment. The cardio-
protective effect of estrogen was abolished by glibenclamide,
suggesting that the cardioprotective effect of estrogen may
result from activation of myocardial KATP channels.
Patients in the preconditioned and estrogen groups
showed that myocardial ischemia was significantly amelio-
rated during the second balloon inflation, as assessed by a
subjective anginal score, ST-segment shift and MLER. The
ST-segment shift and chest pain score noted during the first
inflation in the estrogen-treated patients were indistin-
guishable from those observed during the second inflation in
the preconditioned patients, suggesting that the degree of
protection afforded by estrogen was comparable to that
afforded by previous exposure to ischemia in the precondi-
tioned group. This finding was further corroborated by the
objective observation that in the preconditioned group, the
magnitude of MLER decreased after the second inflation,
whereas in the estrogen-treated group, no significant
changes occurred in this variable during the second inflation
as compared with the first inflation—a feature of precondi-
tioning. Tanonaka et al. (16) showed that preconditioning
induced by estrogen enhanced the reperfusion-induced res-
toration of myocardial high-energy phosphate and attenu-
ated the ischemia-induced increase in tissue lactate content,
consistent with our results showing a reduction of sinus
lactate accumulation. This finding was not consistent with
that of Sbarouni et al. (17), who showed that intracoronary
estrogen administration did not affect the subsequent myo-
cardial tolerance to ischemia. However, the latter study was
not designed to assess the effect of estrogen on ischemic
preconditioning. The investigators did not control the balloon
inflation duration, nor the interval between the two inflations,
both of which are important determinants of ischemic precon-
ditioning. Furthermore, surface electrocardiography was used
to measure the ST-segment changes in that study. Several
Table 3. Doppler Collateral Channels, Chest Pain, ST-Segment Shift and MLER Among the
Five Groups
Variables
Control
(n  10)
PC
(n  10)
Estrogen
(n  10)
PC 
Glibenclamide
(n  10)
Estrogen 
Glibenclamide
(n  10)
Collateral channels (cm)
Inflation 1 2.2 	 0.5 2.0 	 0.4 2.1 	 0.4 2.3 	 0.5 2.1 	 0.3
Inflation 2 2.3 	 0.4 2.1 	 0.5 2.3 	 0.4 2.2 	 0.4 2.1 	 0.4
Chest pain
Inflation 1 5.7 	 0.9 6.4 	 1.6 3.5 	 1.3† 6.8 	 1.0 6.7 	 1.4
Inflation 2 5.9 	 1.0 3.6 	 0.7‡§ 3.3 	 0.7¶ 7.0 	 0.8 6.7 	 1.4
ST-segment shift (mV)*
Inflation 1 1.46 	 0.26 1.36 	 0.23 0.50 	 0.16 1.46 	 0.16 1.49 	 0.24
Inflation 2 1.48 	 0.21 0.43 	 0.15 0.47 	 0.09 1.45 	 0.18 1.45 	 0.13
MLER (%)
Baseline 15 	 14 15 	 17 17 	 25 10 	 17 15 	 16
Inflation 1 122 	 49 141 	 38 48 	 28#** 134 	 64 139 	 37
Inflation 2 124 	 29 41 	 29§ 45 	 30¶ 128 	 31 131 	 34
Data are presented as the mean value 	 SD.
*ST-segment shift was defined as the differences in ST-segment levels between baseline and at the end of the first and second
inflations. †p  0.0001 compared with inflation 1 data from the control, PC, PC  glibenclamide and estrogen  glibenclamide
groups. ‡p  0.005 compared with inflation 2 data from control group. §p  0.0001 compared with inflation 2 data from the
PC  glibenclamide and estrogen  glibenclamide groups. p  0.0001 compared with inflation 1 data within the same group
and inflation 2 data from the control. ¶p  0.0001 compared with inflation 2 data from the control, PC  glibenclamide and
estrogen glibenclamide groups. #p 0.001 compared with inflation 1 data from the control, PC and estrogen  glibenclamide
groups. **p  0.001 compared with inflation 1 data from the PC  glibenclamide group.
MLER  myocardial lactate extraction ratio; other abbreviations as in Table 1.
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reports have shown that during PTCA, transient ischemia was
more readily detected, and with greater sensitivity, on the
intracoronary ECG than on the surface ECG (18).
Estrogen mechanisms and KATP channels. The mecha-
nisms by which estrogen affects ischemic preconditioning
remain undefined. Clearly, estrogen did not exert any
hemodynamic effects, nor was it associated with an increase
in myocardial collateral blood flow at the dose used here.
The results from this study have established similarities
between estrogen and ischemic preconditioning. Ischemic
preconditioning and estrogen appear to share a common
mediator—the KATP channels, although the signal trans-
duction pathway in estrogen treatment, which results in
increased activation of KATP channels, is unknown. One
possible mechanism is that the channel is opened by
adenosine, which is increased by estrogen (19). Adenosine is
one of the agonists binding to membrane receptors to
trigger KATP channels (20). Second, Node et al. (5) dem-
onstrated that estrogen increases the production of nitric
oxide, and previous studies have shown that nitric oxide
facilitates the opening of KATP in cardiac cells (21). Fur-
thermore, estrogen has been shown to induce rapid phar-
macodynamic changes of the G-protein–coupled mechanism,
regulating the potency of opening KATP channels (22).
Clinical implications. This study shows that precondi-
tioning was blocked by glibenclamide, a commonly used
sulfonylurea in patients with diabetes. Previous studies have
shown that diabetic patients have a substantially higher
mortality rate after acute myocardial infarction, as compared
with nondiabetic patients, a circumstance that has been
partly attributed to tablet treatment (23,24). A recent
retrospective study, however, did not find that survival was
influenced by sulfonylurea (25). Because the analysis was
retrospective, it has several shortcomings. Randomized,
prospective studies can better answer the question. Our study
shows that glibenclamide prevents ischemic preconditioning,
which could contribute to excessive mortality from cardiovas-
cular causes in diabetic patients receiving sulfonylurea. The
notion was compatible with the suggestion that high-risk
diabetic patients should switch from sulfonylurea to insulin
when undergoing a coronary intervention (24).
Although cardioprotection has been demonstrated by
short-term loading of estrogen in this study, it does not
necessarily imply the similar benefit in long-term adminis-
tration of estrogen. Epidemiologic studies have repeatedly
demonstrated favorable associations between hormone re-
placement therapy and cardiovascular morbidity and mor-
tality. However, the Heart and Estrogen/progestin Replace-
ment Study (HERS), the first randomized trial of hormone
replacement therapy, showed no overall benefit in the
secondary prevention of heart disease in menopausal women
(26). Clearly, the use of hormone replacement therapy for
secondary prevention of heart disease is more complex than
was initially believed. A more detailed analysis of the HERS
results showed that the risk of heart disease was reduced at
three to five years, but this reduction was offset by a 50%
higher cardiac event rate during the first year. This time
trend pattern of an early increase and late reduction in risk
may be reconciled with epidemiologic studies. The early
mortality might be related to an increase in thrombosis risk,
whereas the late benefit might be related to a decreased risk
of atherosclerosis (26). Besides, the drug used in HERS was
a combination of estrogen and progestin, and progestin has
been shown to attenuate the cardioprotective effect of
estrogen. It is likely that progestin may have contributed to
the increase in infarction rates. However, in the Estrogen
Replacement and Atherosclerosis trial, there were no ben-
efits in the group treated with estrogen alone (27). Thus,
one should be cautious to apply our results to patients using
estrogen over a long term.
Study limitations. There were several limitations of this
study. First, there appears to be a bias toward the inclusion
of more males in this study (45 men and 5 women). Patients
underwent cardiac catheterization to assess the severity of
coronary atherosclerosis, which is more prevalent in males
than in females (28). Thus, the effects of short-term
administration of estrogen in women need more clinical
studies to confirm the benefits. Second, blood samples for
measuring lactate production were obtained 10 to 15 s after
balloon deflation. Because coronary sinus flow was not
measured, our results were not expressed in terms of lactate
efflux. The less elevated concentrations in the coronary sinus
underestimated a reduction in lactate production in the
preconditioned and estrogen-treated groups, because the
relative hyperemia was significantly lower than that in the
control group (29). Third, the interval between the two
balloon inflations was 1 min in the non-preconditioned groups.
No previous studies in humans have shown whether the
interval was adequate to re-establish a nonischemic baseline
value. However, the baseline re-establishment was confirmed
in the study assessed by intracoronary electrocardiography and
chest pain, although no lactate measurement was performed at
the time. The observation was in agreement with the finding of
Dunn et al. (30), showing that after a brief coronary occlusion,
lactate from the coronary sinus returned to control levels within
30 s after ligation release in dogs.
Fourth, previous studies have demonstrated that intra-
coronary infusion of a large dose of glibenclamide (50 g/kg/
min) reduced coronary blood flow and elevated the ST
segment (31). Kondo et al. (32) demonstrated no ST-
segment changes at the dose of 1 mg/kg. The low dose of
glibenclamide used in this study should not have created any
ST-segment changes. Another possibility is that the open-
ing of KATP channels leads to elevation of the ST segment
because of a shortening of the action potential duration and
accumulation of extracellular potassium concentrations dur-
ing myocardial ischemia (33), and those were blocked by
glibenclamide. Thus, it is possible that there was an under-
estimation of the blockade of estrogen-induced precondi-
tioning by glibenclamide in our patients. Finally, a potential
problem with the present study is the use of glibenclamide
as an antagonist of KATP channels when there are many
876 Lee et al. JACC Vol. 39, No. 5, 2002
Estrogen and KATP Channel March 6, 2002:871–7
potential nonspecific targets of glibenclamide, including the
inhibition of Na channels and the opening of Ca2
channels (34). These alternative effects could confound the
interpretation of the present study. Use of a more selective
antagonist of KATP channels, 5-hydroxydecanoate, would have
strengthened the hypothesis. However, 5-hydroxydecanoate is
not available for use in humans.
Conclusions. The present study demonstrates that intra-
coronary administration of estrogen before PTCA enhances
the tolerance of the heart to subsequent ischemia, as
assessed by clinical, ECG and metabolic evidence, in a
manner analogous to that observed during ischemic precon-
ditioning. Responses are inhibited by the KATP antagonist
glibenclamide, suggesting that they act on the same sites.
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